Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$7.85 USD
+0.20 (2.61%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.84 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Fulcrum Therapeutics, Inc. [FULC]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fulcrum Looks to "REACH" New Heights in 2024: Reit. Buy and Modulating our PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fulcrum?s Pipeline Looks For Balance Heading into 2024; Reit. Buy and $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Removal of ?6058?s Clinical Hold Lights a Clearer Pathway to SCD; Upgrading to Buy and $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revisiting The Potential of REACH, as FHTX-6058?s Future Remains Unclear; Reit. Neutral and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hematologic Malignancy FDA Hold Remains a Difficult Hurdle; Reit. Neutral and Modulating PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unclear If Hematologic Malignancies Stem From A Class Effect or Compound; Downgrading to Neutral; PT Down To $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Curious Clinical Hold, Impacts FTX-6058 Development in SCD; Reiterate Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Progress From FTX-6058 and Losmapimod Shape Long/Short-Term Thesis; Reit. Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fulcrum Doubles Down on FTX-6058 and Losmapimod; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial FTX-6058 Data in SCD, Likely to Be Met With a Polarizing Reaction
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bullish Ahead of FTX-6058 Data at EHA; Reit. Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fulcrum?s FSHD KOL Event Sheds Light on RWS as a Viable Primary Endpoint
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOLs Are Optimistic on REACH Study, But Highlight Many Unknowns in FSHD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 REACH Initiating in 2Q22 Along with FTX-6058 Phase 1b Data; Reit. Buy, $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FTX-6058 Continues to Impress at Higher Doses, Increasing Hopes For Efficacy in SCD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FTX-6058 Continues to Generate Interest, Update Expected by YE21; Reit Buy and $40PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FTX-6058 Exceeds Investor Expectations; Reit Buy and Raising Our PT to $40 from $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive FTX-6058 Phase 1 Data Further De-risks EED Targeting in SCD.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Fulcrum Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ReDUX4 Misses Primary Endpoint, Though Clinical Benefit Seen Across Secondary Endpoints
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A